JP Morgan resumed coverage on Esperion Therapeutics
$ESPR
Biotechnology: Pharmaceutical Preparations
Health Care
JP Morgan resumed coverage of Esperion Therapeutics with a rating of Neutral
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/1/2026 | Buy → Neutral | H.C. Wainwright | |
| 11/25/2025 | $9.00 | Overweight | Piper Sandler |
| 12/18/2024 | $4.00 | Neutral | Goldman |
| 12/17/2024 | $8.00 | Overweight | Cantor Fitzgerald |
| 6/20/2024 | $2.50 | Neutral → Underperform | BofA Securities |
| 1/3/2024 | Buy → Neutral | BofA Securities | |
| 11/20/2023 | Neutral | JP Morgan | |
| 8/1/2023 | Under Perform → Market Perform | Northland Capital |
– Bempedoic Acid Lowered LDL-C and Was Well Tolerated in Children Aged 6-17 Years – – A Secondary Analysis of CLEAR Outcomes Reports on Patient Factors Associated With 30% or Greater Reduction in LDL-C in Statin Intolerant Adults – ANN ARBOR, Mich., May 26, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced the presentation of results from a Phase 2 study of bempedoic acid in children, along with an additional post hoc analysis from CLEAR Outcomes describing patient traits associated an enhanced LDL-C lowering with bempedoic acid. These data were presented as moderated Science at a Glance sessions at the European Atherosclerosis Society (EAS) Congress 2026 taking place on Ma
ANN ARBOR, Mich., May 14, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that on May 12 2026, the Company granted 23 new employees 260,000 restricted stock units (RSUs) under Esperion's 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Esperion, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules. Each RSU will vest and become exercisable as to 25 percent of the shares on
– Presentations Examine Findings From the Pediatric Phase 2 Study, As Well As Factors Associated With Enhanced LDL-C Reductions in Adult Patients Enrolled in Clear Outcomes – – Pediatric Phase 2 Study Demonstrated Bempedoic Acid Treatment Reduced LDL-C in Children with Heterozygous Familial Hypercholesterolemia (HeFH) Congruent with Reductions in Adult Exposures – – New Analyses from CLEAR Outcomes Trial Identified Factors Associated With Enhanced LDL-C Reductions in Adult Patients – ANN ARBOR, Mich., May 13, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that two new abstracts and three encore abstracts have been accepted for presentation at the European Atherosclerosi
Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-16) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211617, Application Classification: Efficacy
Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-17) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211617, Application Classification: Efficacy
Submission status for ESPERION THERAPS INC's drug NEXLETOL (SUPPL-13) with active ingredient BEMPEDOIC ACID has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211616, Application Classification: Efficacy
8-K - Esperion Therapeutics, Inc. (0001434868) (Filer)
PREM14A - Esperion Therapeutics, Inc. (0001434868) (Filer)
10-Q - Esperion Therapeutics, Inc. (0001434868) (Filer)
4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
H.C. Wainwright downgraded Esperion Therapeutics from Buy to Neutral
Piper Sandler initiated coverage of Esperion Therapeutics with a rating of Overweight and set a new price target of $9.00
Goldman initiated coverage of Esperion Therapeutics with a rating of Neutral and set a new price target of $4.00
SC 13G/A - Esperion Therapeutics, Inc. (0001434868) (Subject)
SC 13G/A - Esperion Therapeutics, Inc. (0001434868) (Subject)
SC 13G/A - Esperion Therapeutics, Inc. (0001434868) (Subject)
Esperion shareholders to receive $3.16 per share in cash at closing, plus the right to participate in up to $100 million in aggregate contingent milestone payments Represents total equity value of up to approximately $1.1 billion ANN ARBOR, Mich., May 01, 2026 (GLOBE NEWSWIRE) -- Esperion Therapeutics (NASDAQ:ESPR) ("Esperion," or the "Company"), a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative cardiometabolic and rare/orphan disease therapies, and ARCHIMED ("ARCHIMED"), a leading investment firm focused exclusively on healthcare industries, today announced that they have entered into a definitive agreement under which funds managed by ARCHIM
ANN ARBOR, Mich., April 23, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced it will report first quarter 2026 financial results before the market opens on Thursday, May 7, 2026. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days. About Esperion Therapeutics Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical c
– FY25 Total Revenue Grew 21% Y/Y to $403.1 Million; FY25 U.S. Net Product Revenue Grew 38% Y/Y to $159.6 Million – – Q4 2025 U.S. Net Product Revenue Grew ~38% Y/Y to $43.7 Million; Q4 2025 Total Revenue Grew 144% Y/Y to $168.4 Million – – Q4 Retail Prescription Equivalents Grew 34% Y/Y and 11.3% Q/Q – – Agreement to Acquire Corstasis Therapeutics to Accelerate Growth and Expand Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) – – Conference Call and Webcast Today at 8:00 a.m. ET – ANN ARBOR, Mich., March 10, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today reported financial results for the fourth quarter and full year ended December 31, 2025, and highlighted co
– Brings Extensive Executive Leadership Driving Commercial Strategies That Enhance Sales and Marketing Performance – ANN ARBOR, Mich., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced the appointment of John Harlow as the Company's Chief Commercial Officer, effective November 17, 2025. Mr. Harlow will join Esperion's Executive Leadership Team and will report directly to Sheldon Koenig, President and CEO of Esperion. "We are thrilled to welcome John as our Chief Commercial Officer at such a pivotal time in Esperion's growth, as we continue to expand adoption of our products in the U.S. and increase our global footprint," said Koenig. "John's deep domain expertise
ANN ARBOR, Mich., July 01, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced it has appointed Craig Thompson, Chief Executive Officer of Cerevance, to its Board of Directors. Mr. Thompson will serve as an independent director. With Mr. Thompson's appointment, Esperion's Board of Directors now comprises eight members. "We are thrilled to welcome Craig to our Board of Directors. With more than two decades of biopharmaceutical industry leadership and a proven track record advancing innovative therapies, Craig brings a wealth of strategic insight and operational expertise that will be invaluable as we continue to expand our impact in cardiovascular and cardiometabolic drug devel
– Expands Development Portfolio with Introduction of a Novel Program Targeting PSC – – Confirms Highly Specific Allosteric ACLY Inhibitor Shown to Reduce Liver Injury, Inflammation and Fibrosis Across Multiple PSC-Relevant Pre-Clinical Models – – Demonstrates Internal R&D Capabilities with Wholly Owned, Next-Generation Candidates Targeting Liver and Kidney Disease – – Esperion to Webcast R&D Day Event Today at 9:00 a.m. ET – ANN ARBOR, Mich., April 24, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the Company plans to highlight new research supporting its lead development candidates for the treatment of primary sclerosing cholangitis (PSC), a rare and progressive